Toxoplasma gondii Infection in the United States, 1999–2000

Infection with Toxoplasma gondii can lead to congenital and acquired disease, resulting in loss of vision and neurologic illness. We tested sera collected in the National Health and Examination Survey (NHANES) from 1999–2000 for T. gondii–specific immunoglobulin G antibodies and compared these resul...

Full description

Bibliographic Details
Main Authors: Jeffrey L. Jones, Deanna Kruszon-Moran, Marianna Wilson
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2003-11-01
Series:Emerging Infectious Diseases
Subjects:
Online Access:https://wwwnc.cdc.gov/eid/article/9/11/03-0098_article
id doaj-e81c52ff5fac4bcdb0985cbe230be1cf
record_format Article
spelling doaj-e81c52ff5fac4bcdb0985cbe230be1cf2020-11-24T22:15:53ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592003-11-019111371137410.3201/eid0911.030098Toxoplasma gondii Infection in the United States, 1999–2000Jeffrey L. JonesDeanna Kruszon-MoranMarianna WilsonInfection with Toxoplasma gondii can lead to congenital and acquired disease, resulting in loss of vision and neurologic illness. We tested sera collected in the National Health and Examination Survey (NHANES) from 1999–2000 for T. gondii–specific immunoglobulin G antibodies and compared these results with results from sera obtained in the NHANES III survey (1988–1994). NHANES collects data on a nationally representative sample of the U.S. civilian population. Of 4,234 persons 12–49 years of age in NHANES 1999–2000, 15.8% (age-adjusted, 95% confidence limits [CL] 13.5, 18.1) were antibody positive; among women (n=2,221) 14.9% (age-adjusted, 95% CL 12.5, 17.4) were antibody positive. T. gondii antibody prevalence was higher among non-Hispanic black persons than among non-Hispanic white persons (age-adjusted prevalence 19.2% vs. 12.1%, p=0.003) and increased with age. No statistically significant differences were found between T. gondii antibody prevalence in NHANES 1999–2000, and NHANES III. T. gondii antibody prevalence has remained stable over the past 10 years in the United States.https://wwwnc.cdc.gov/eid/article/9/11/03-0098_articleprevalenceToxoplasma gondiitoxoplasmosisUnited States
collection DOAJ
language English
format Article
sources DOAJ
author Jeffrey L. Jones
Deanna Kruszon-Moran
Marianna Wilson
spellingShingle Jeffrey L. Jones
Deanna Kruszon-Moran
Marianna Wilson
Toxoplasma gondii Infection in the United States, 1999–2000
Emerging Infectious Diseases
prevalence
Toxoplasma gondii
toxoplasmosis
United States
author_facet Jeffrey L. Jones
Deanna Kruszon-Moran
Marianna Wilson
author_sort Jeffrey L. Jones
title Toxoplasma gondii Infection in the United States, 1999–2000
title_short Toxoplasma gondii Infection in the United States, 1999–2000
title_full Toxoplasma gondii Infection in the United States, 1999–2000
title_fullStr Toxoplasma gondii Infection in the United States, 1999–2000
title_full_unstemmed Toxoplasma gondii Infection in the United States, 1999–2000
title_sort toxoplasma gondii infection in the united states, 1999–2000
publisher Centers for Disease Control and Prevention
series Emerging Infectious Diseases
issn 1080-6040
1080-6059
publishDate 2003-11-01
description Infection with Toxoplasma gondii can lead to congenital and acquired disease, resulting in loss of vision and neurologic illness. We tested sera collected in the National Health and Examination Survey (NHANES) from 1999–2000 for T. gondii–specific immunoglobulin G antibodies and compared these results with results from sera obtained in the NHANES III survey (1988–1994). NHANES collects data on a nationally representative sample of the U.S. civilian population. Of 4,234 persons 12–49 years of age in NHANES 1999–2000, 15.8% (age-adjusted, 95% confidence limits [CL] 13.5, 18.1) were antibody positive; among women (n=2,221) 14.9% (age-adjusted, 95% CL 12.5, 17.4) were antibody positive. T. gondii antibody prevalence was higher among non-Hispanic black persons than among non-Hispanic white persons (age-adjusted prevalence 19.2% vs. 12.1%, p=0.003) and increased with age. No statistically significant differences were found between T. gondii antibody prevalence in NHANES 1999–2000, and NHANES III. T. gondii antibody prevalence has remained stable over the past 10 years in the United States.
topic prevalence
Toxoplasma gondii
toxoplasmosis
United States
url https://wwwnc.cdc.gov/eid/article/9/11/03-0098_article
work_keys_str_mv AT jeffreyljones toxoplasmagondiiinfectionintheunitedstates19992000
AT deannakruszonmoran toxoplasmagondiiinfectionintheunitedstates19992000
AT mariannawilson toxoplasmagondiiinfectionintheunitedstates19992000
_version_ 1725792422114361344